Upstream Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	2.72	2.37	2.38
Revenue Growth (YoY)	22.60%	-0.42%	-
Gross Profit	2.72	2.37	2.38
Selling, General & Admin	23.43	17.17	10.7
Research & Development	100.87	62.97	31.8
Total Operating Expenses	124.29	80.13	42.49
Operating Income	-121.57	-77.76	-40.11
Interest Income	17.15	12.12	4.17
Other Non-Operating Income (Expense)	-	2.84	15.41
Total Non-Operating Income (Expense)	17.15	14.96	19.58
Pretax Income	-104.42	-62.81	-20.54
Net Income	-110.06	-76.4	-38.26
Net Income Attributable to Preferred Dividends	5.59	13.59	17.72
Net Income to Common	-110.06	-76.4	-38.26
Shares Outstanding (Basic)	39	14	3
Shares Outstanding (Diluted)	39	14	3
Shares Change (YoY)	1207.07%	363.22%	-
EPS (Basic)	4.36	-5.58	-12.95
EPS (Diluted)	4.36	-5.58	-12.95
Free Cash Flow	-113.98	-59.68	-38.07
Free Cash Flow Per Share	-2.92	-4.36	-12.89
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-4464.60%	-3281.18%	-1685.46%
Profit Margin	-3834.63%	-2650.04%	-862.90%
FCF Margin	-4185.75%	-2518.27%	-1599.58%
EBITDA	-121.42	-77.68	-40.05
EBITDA Margin	-4459.16%	-3277.43%	-1682.94%
EBIT	-121.57	-77.76	-40.11
EBIT Margin	-4464.60%	-3281.18%	-1685.46%

Updated Aug 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q